Innovation 50 Medherant
23rd September 2019
Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch
Blogs
John Burt
25th June 2019
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a u
Press Releases
BVCA Management Team Awards
14th June 2019
Medherant enjoyed a great evening at the Midlands BVCA Management Team Awards last night.
General News
21st May 2019
Coventry, UK, 21st May 2019 / Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS dise
Press Releases
13th February 2019
Pain affects everyone at some time in their life, be it chronic arthritis or a one-off injury.
Blogs
Silicone republic 100
11th February 2019
Medherant has been included in the Silicone Republic Europe Start-up 100 for 2019 which looks at the companies to watch this year in e-commerce and fintech, deeptech, hardware and IoT, and medtech and life sciences.
General News
21st January 2019
Last year was another busy year for Medherant with a significant milestone reached when we received positive results from the first clinical trials with our TEPI Patch® technology.
Blogs
5th November 2018
Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI Patch®.
Press Releases
3rd October 2018
Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medicines Manufacturing Grant by Innovate UK.
Press Releases
CPhI awards logo
11th September 2018
Medherant has been shortlisted for the CPhI Pharma Awards in both the Formulation and Drug Delivery Devices categories for its TEPI Patch® technology.
General News

Pages